Sun Pharmaceutical has signed agreement with Strides Arcolab to sell Ranbaxy's two divisions (Solus and Solus Care) in central nervous system (CNS) for Rs 165 crore. The agreement involves transfer of marketing divisions, along with employees to Strides. As per IMS July 2015 MAT report, the products of these two divisions together accounted for approximately Rs 92 crore in sales.